Biotechnology Assets SA
MAD:BST

Watchlist Manager
Biotechnology Assets SA Logo
Biotechnology Assets SA
MAD:BST
Watchlist
Price: 0.226 EUR -2.59% Market Closed
Market Cap: 16.5m EUR
Section:
 

Relative Value

The Relative Value of one BST stock under the Base Case scenario is 0.256 EUR. Compared to the current market price of 0.226 EUR, Biotechnology Assets SA is Undervalued by 12%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BST Relative Value
Base Case
0.256 EUR
Undervaluation 12%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.9
P/S
P/S
Price to Sales
5.9
vs History
14
vs Industry
52
Median 3Y
6.8
Median 5Y
6.3
Industry
7.8
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
9
Median 3Y
-6.4
Median 5Y
-5.5
Industry
24.1
More Details
26.8
P/OCF
P/OCF
Price to OCF
26.8
vs History
26
vs Industry
8
Median 3Y
21.4
Median 5Y
1.4
Industry
21.8
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
8
Median 3Y
-11.8
Median 5Y
-5
Industry
23.8
More Details
2.4
P/B
P/B
Price to Book Value
2.4
vs History
39
vs Industry
32
Median 3Y
3
Median 5Y
3
Industry
3.3
More Details
6.1
EV/S
EV/S
Enterprise Value to Sales
6.1
vs History
22
vs Industry
43
Median 3Y
7.2
Median 5Y
6.8
Industry
8
More Details
7.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.4
vs History
41
vs Industry
40
Median 3Y
9.9
Median 5Y
9.6
Industry
10.3
More Details
13.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
13.3
vs History
39
vs Industry
12
Median 3Y
19.2
Median 5Y
14.5
Industry
6.3
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
10
Median 3Y
-13.6
Median 5Y
-13.5
Industry
6.7
More Details
27.6
EV/OCF
EV/OCF
Enterprise Value to OCF
27.6
vs History
26
vs Industry
8
Median 3Y
22.1
Median 5Y
1.7
Industry
7.9
More Details
145.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
145.8
vs History
7
vs Industry
5
Median 3Y
-11.6
Median 5Y
-4.2
Industry
6.3
More Details
1.3
EV/IC
EV/IC
Enterprise Value to IC
1.3
vs History
7
vs Industry
50
Median 3Y
1.4
Median 5Y
1.3
Industry
5.5
More Details

Multiples Across Competitors

BST Competitors Multiples
Biotechnology Assets SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
ES
Biotechnology Assets SA
MAD:BST
15.4m EUR 5.9 -7.4 13.3 -13.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 710 712 -160 222 -194 560.6 -192 340.5
US
Abbvie Inc
NYSE:ABBV
407.1B USD 6.8 173.4 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
179.3B USD 5 25.6 18.4 18.4
US
Gilead Sciences Inc
NASDAQ:GILD
157.2B USD 5.4 19.4 13 13
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.6B USD 9.9 31.7 23.3 24.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 089.8 -533.3 -580.7 -565.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD 5.8 18 17.2 19.5
AU
CSL Ltd
ASX:CSL
85.1B AUD 3.6 18.9 12.7 15.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.5B USD 16.7 1 227.2 161.3 195.6
NL
argenx SE
XBRU:ARGX
44.2B EUR 14.4 33.9 58.5 60.1
P/E Multiple
Earnings Growth PEG
ES
Biotechnology Assets SA
MAD:BST
Average P/E: 193.5
Negative Multiple: -7.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 222 N/A N/A
US
Abbvie Inc
NYSE:ABBV
173.4
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.6
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.4
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.7
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
9%
2
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 227.2
N/A N/A
NL
argenx SE
XBRU:ARGX
33.9
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ES
Biotechnology Assets SA
MAD:BST
Average EV/EBITDA: 37.2
13.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 560.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.4
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
13
7%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
11%
1.6
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
161.3
N/A N/A
NL
argenx SE
XBRU:ARGX
58.5
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ES
Biotechnology Assets SA
MAD:BST
Average EV/EBIT: 46.3
Negative Multiple: -13.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 340.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.4
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.5
13%
1.5
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
195.6
N/A N/A
NL
argenx SE
XBRU:ARGX
60.1
N/A N/A

See Also

Summary
BST intrinsic value, competitors valuation, and company profile.
DCF Valuation
BST stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BST stock valuation using valuation multiples.
Wall Street Estimates
BST price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BST stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 304,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.